HGC Investment Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

HGC Investment Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-79,150	Closed	-$794K	–	397
2022 Q3	$794K	Sell	79,150 -79,150	-50%	-$789K	0.05%	242
2022 Q2	$1.57M	Buy	158,300 +79,150	+100%	+$786K	0.05%	281
2022 Q1	$781K	Buy	+79,150	New	+$785K	0.05%	258

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HGC Investment Management's EUCRU Position: Q4 2022 in Review

HGC Investment Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 79,150 shares — an estimated $794K sold.

HGC Investment Management first reported a position in EUCRU in Q1 2022 and held it in 3 quarters. The position peaked at $1.57M in Q2 2022. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

HGC Investment Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
HGC Investment Management sold 79,150 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $794K.
HGC Investment Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2022 and held it in 3 quarters.
HGC Investment Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $1.57M in Q2 2022.
6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on HGC Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.